Fairvalue-Calculator Fairvalue-Calculator
EN DE

Ahn-Gook Pharmaceutical Co (001540) Fair Value & Analysis

Healthcare · KR · Market cap 129B KRW

Price9,790 KRW
Fair Value14,480 KRW
Upside+47.9%
Quality95/100
Evidence: High Range 10,860 KRW – 18,100 KRW

Fair value as of: Jun 25, 2026

Analysis

Ahn-Gook Pharmaceutical Co (001540) currently trades at 9,790 KRW, while our model-based Fair Value estimate is 14,480 KRW — implying the stock looks roughly 47.9% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% United Therapeutics Corporation (U2TH34) -2%

Frequently asked questions

Is Ahn-Gook Pharmaceutical Co (001540) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 14,480 KRW versus a price of 9,790 KRW — about +48% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 001540?
Our 21-model fair value for Ahn-Gook Pharmaceutical Co is 14,480 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 9,790 KRW.
What is the quality score of 001540?
Ahn-Gook Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.